Zepbound And Liver Disease - Listen - On The Pen: The Weekly Dose

Zepbound And Liver Disease

Listen now

Description

Send us a Text Message.Eli Lilly's phase 2 SYNERGY-NASH study shows tirzepatide effectively resolves MASH and improves fibrosis, offering hope for millions. Read more here: https://www.onthepen.com/post/tirzepatide-shows-promise-in-treating-mash-key-findings-from-the-synergy-nash-studySupport the Show.MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/joinSOCIAL LINKShttps://www.tikt...

More Episodes

See all »

Novo Nordisk's War on Compound Semaglutide, Maritide Has Some Negative News

Send us a textIn this episode of On The Pen: The Weekly Dose, host Dave Knapp dives into the latest updates in obesity medicine, with insightful takes on current treatment breakthroughs, new medication approvals, and tips on navigating healthcare options. This week’s deep dive also touches on...

Published 11/12/24

Viking Therapeutics and AstraZeneca Steal The Show at Obesity Week!

Send us a textSemaglutide News: https://www.onthepen.com/post/select-trial-update-semaglutide-s-cardiovascular-benefits-and-psychiatric-safety-profile-highlighteViking Therapeutics News:https://www.onthepen.com/post/vk2735-vikingtideAstraZeneca News:...

Published 11/05/24

On The Pen With Dave Knapp

Published 11/05/24